Clinical trials: Musculoskeletal Diseases
Osteoporosis
A Dose Selection Study of Oral Recombinant Salmon Calcitonin (rsCT) in Normal, Healthy, Postmenopausal Women
This study compares the performance of different doses of oral recombinant salmon calcitonin (rsCT).
- Trial name
- NCT00620854
- Testing
- Recombinant Salmon Calcitonin (rsCT), Oral Tablet, Nasal Spray
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Tarsa Therapeutics, Inc.
Rheumatoid Arthritis
A Study of the Safety of Rituximab in Combination With Other Anti-Rheumatic Drugs in Subjects With Active Rheumatoid Arthritis
This is a Phase III, open-label study of a total of approximately 560 subjects with active rheumatoid arthritis (RA) who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs).
- Trial name
- SUNDIAL (NCT00443651)
- Testing
- Rituximab, Anti-inflammatory drugs
- Volunteers
- 578 people
- Sponsor
- Genentech, Inc.
Osteoporosis, Osteoarthritis
OSTEOMICS: Identifying Regulators of Bone Homeostasis
Diseases of bone associated with ageing, including osteoporosis (OP) and osteoarthritis (OA), reduce bone mass, bone strength and joint integrity.
- Conditions
- Osteoporosis, Osteoarthritis, Bone Diseases, Bone Fracture
- Trial name
- OSTEOMICS (NCT05732870)
- Testing
- Relevant orthopaedic surgery
- Where
- 8 sites in United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Relation Therapeutics
Degenerative Disc Disease (DDD)
HYDRAFIL-D: HYDRogel Augmentation For Intervertebral Lumbar Discs
A multi-center, prospective, dual arm, randomized, controlled pivotal study to evaluate the safety and effectiveness of the ReGelTec HYDRAFIL™ System.
- Trial name
- HYDRAFIL-D (NCT06011551)
- Testing
- The ReGelTec HYDRAFIL™ System, Conservative Care Management
- Where
- 16 sites in United States, Canada
- Volunteers
- 225 people
- Sponsor
- ReGelTec, Inc.
Physical Activity, Muscle Recovery
Effect of NMN on Muscle Recovery and Physical Capacity in Healthy Volunteers With Moderate Physical Activity
The purpose of this study is to evaluate the effect of NMN supplementation (250 and 500 mg/day over 38 days) compared to placebo in healthy volunteers with moderate physical activity on muscle recovery, physical capacity…
- Trial name
- NCT04664361
- Testing
- Nicotinamide mononucleotide
- Where
- France
- Volunteers
- 131 people, healthy volunteers welcome
- Sponsor
- Seneque SA
Rheumatoid Arthritis
Expanded Access Trial of Belimumab Antibody in RA Patients Who Were Previously Treated Under HGS Protocol LBRA99
An expanded access trial of belimumab for named patients who participated in LBRA99.
- Trial name
- LBRA99 (NCT00931086)
- Testing
- belimumab
- Where
- United States
- Sponsor
- Human Genome Sciences Inc., a GSK Company
Osteoarthritis
Use of Synvisc® in Knee Osteoarthritis - Medico-economical Study
The USAGE study aims at assessing on a long-term period (two years in average) the outcome in clinical or economical term of patients with knee osteoarthritis (OA) treated or not with Synvisc®, in the 1139.4 clinical trial.
- Trial name
- NCT02195505
- Volunteers
- 374 people
- Sponsor
- Boehringer Ingelheim
Rheumatoid Arthritis
Impact of Anti-citrullinated Protein Antibody Status on Treatment Response and Treatment Persistence in Participants With Rheumatoid Arthritis (RA) Who Are Treated With Abatacept or Tumor Necrosis Factor Inhibitors in Australia
An observational study assessing the impact of anti-citrullinated antibody (ACPA) in rheumatoid arthritis (RA) participants who have received abatacept or tumour necrosis factor inhibitors (TNFi) from the Optimising Patient…
- Trial name
- NCT03663829
- Testing
- Non-Interventional
- Where
- Australia
- Volunteers
- 2,052 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
Oral CF101 Tablets and Methotrexate Treatment in Rheumatoid Arthritis Patients
This trial will test the hypothesis that the addition of CF101, a novel anti-inflammatory agent, will improve the clinical condition of patients with rheumatoid arthritis who still have active joint inflammation despite taking…
- Trial name
- NCT00556894
- Testing
- CF101
- Where
- 26 sites in Bulgaria, Czechia and 4 more
- Volunteers
- 253 people
- Sponsor
- Can-Fite BioPharma
Rheumatoid Arthritis (RA)
A Phase 3 Study of Abatacept in Chinese Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
The primary objective of this study is to demonstrate superior efficacy of abatacept 125mg administrated SC weekly comparing to placebo after 24 weeks treatment in Chinese subjects who have active rheumatoid arthritis, are…
- Trial name
- NCT02722694
- Testing
- Subcutaneous(SC) Abatacept, Methotrexate
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Arthritis, Rheumatoid
Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SKI-O-703 in Healthy Volunteers
This double-blind, placebo-controlled, multiple ascending dose study is designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of SKI-O-703 in healthy volunteers.
- Trial name
- NCT03315494
- Testing
- SKI-O-703 capsule
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Oscotec Inc.
Inflammation, Rheumatoid Arthritis
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0114-0006 in Subjects With Active Rheumatoid Arthritis
This trial is conducted in Europe. The aim of the trial is to evaluate the change in disease activity following intravenous (i.v.) administration of two doses of NNC0114-0006 compared to placebo in subjects with active rheumatoid…
- Trial name
- NCT01647451
- Testing
- NNC0114-0006
- Where
- 33 sites in Bulgaria, Hungary and 5 more
- Volunteers
- 62 people
- Sponsor
- Novo Nordisk A/S
Knee Osteoarthritis
Autologous Adipose Tissue Derived Mesenchymal Stem Cells Therapy for Patients With Knee Osteoarthritis
Two injections in total and 3 ml autologous adipose-tissue-derived stem cells(haMSCs) for each injection; time-points for intervention: 1) initial injection; 2) 3 weeks following initial injection.
- Trial name
- NCT01809769
- Testing
- Mesenchymal stem cells low-dose group, Mesenchymal stem cells mid-dose group, Mesenchymal stem cells high-dose group
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Shanghai AbelZeta Ltd.
Systemic Juvenile Idiopathic Arthritis
Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)
This study assessed the initial efficacy and safety of canakinumab over a 4 week period in patients with systemic juvenile idiopathic arthritis (SJIA) having a flare.
- Trial name
- β-SPECIFIC 1 (NCT00886769)
- Testing
- Canakinumab
- Where
- 91 sites in United States, Argentina and 20 more
- Volunteers
- 84 people
- Sponsor
- Novartis Pharmaceuticals
Osteoarthritis, Post-traumatic Arthritis
Foundation Knee Study - Retrospective
The purpose of this study is to evaluate the use and efficacy of the Encore Foundation Knee System in a group of 200 patients for whom data has already been collected.
- Conditions
- Osteoarthritis, Post-traumatic Arthritis, Inflammatory Tissue Disorders, Arthritis Secondary to Other Diseases
- Trial name
- NCT00764894
- Testing
- Foundation Knee
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Encore Medical, L.P.
Osteoporosis, Postmenopausal
FLEX - Long-term Extension of FIT (Fracture Intervention Trial)(0217-051)
This study was conducted among women who had previously received alendronate for 3 to 6 years during the Fracture Intervention Trial (FIT).
- Trial name
- NCT00398931
- Testing
- MK0217, alendronate sodium / Duration of Treatment : 5 Years
- Volunteers
- 1,099 people
- Sponsor
- Organon and Co
Rheumatoid Arthritis
Economic Burden in Adult Patients Diagnosed With Rheumatoid Arthritis (RA) Receiving Treatment With Biologic Disease-modifying Antirheumatic Drugs (bDMARDs)
The purpose of this study is to explore the differences in productivity loss and costs between patients being treated for rheumatoid arthritis (RA) with biologic disease-modifying antirheumatic drugs (bDMARDs) compared to…
- Trial name
- NCT01136694
- Volunteers
- 695 people
- Sponsor
- Bristol-Myers Squibb
Spondylitis, Ankylosing
16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis
The purpose of this study is to provide 16-week efficacy, safety and tolerability data versus placebo to support the use of secukinumab 150 mg by subcutaneous (s.c.) self-administration with or without a loading regimen and…
- Trial name
- MEASURE4 (NCT02159053)
- Testing
- Secukinumab
- Where
- 90 sites in United States, Australia and 17 more
- Volunteers
- 350 people
- Sponsor
- Novartis Pharmaceuticals
Spasticity
Study of Intramuscular Injections of OnabotulinumtoxinA to Assess Change in Disease Activity in Pediatric Participants With Spasticity Associated With Cerebral Palsy
Spasticity is often observed as muscle tightness and stiffness in the upper and/or lower limbs. Upper limb spasticity can interfere with joint movement and its severity can range from mild to severe.
- Trial name
- NCT06150729
- Where
- 8 sites in Mexico
- Volunteers
- 107 people
- Sponsor
- AbbVie
Osteoarthritis, Osteo Arthritis Knee
Adipose-Derived Biocellular Regenerative Therapy for Osteoarthritis
Use of Biocellular and cellular approaches to treatment of Osteoarthritis (OA), musculoskeletal aging processes, pain, and degenerative changes are to be studied with minimally invasive protocols, and non-pharmaceutical means to…
- Conditions
- Osteoarthritis, Osteo Arthritis Knee, Osteo Arthritis Shoulders, Osteoarthritis of Multiple Joints
- Trial name
- GARM-MSK-ALD (NCT04238143)
- Testing
- Tissue Stromal Vascular Fraction (tSVF) Arm 1, PRP Concentrate Arm 1, Tissue Stromal Vascular Fraction (tSVF) Arm 2
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Healeon Medical Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.